A

Actinium Pharmaceuticals
D

ATNM

1.43000
USD
-0.04
(-2.39%)
Market Closed
Volume
4,811
EPS
-1
Div Yield
-
P/E
-1
Market Cap
44,610,124
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    More
News

Title: Actinium Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.